To investigate clinical efficacy and safety of 2 certolizumab pegol ( CZP ) maintenance dosing regimens plus methotrexate ( MTX ) in active rheumatoid arthritis ( RA ) patients achieving the American College of Rheumatology 20 % improvement criteria ( ACR20 ) after the CZP 200 mg every 2 weeks open-label run-in period .